• Formation Bio Expands AI Capabilities, Element Biosciences Commercializing Platform, More

    Bio-IT World | Formation Bio raises $372 million in Series D for their AI-driven drug discovery platform; Element Biosciences nets $277 million to launch combined sequencing and cyto-profiling platform; and more.

    Jul 24, 2024
  • AI Could Assist in the Quest for New Antibiotics

    Bio-IT World | Antimicrobial resistance (AMR) is “on every thinking individual’s list of existential threats,” as well as one of the cheapest ones that can be solved relative to others such as hunger and climate change. The answers will come by melding human and machine intelligence in the search for new antibiotics.

    Jul 23, 2024
  • Ambitious IDMP Standards Leave Little Breathing Space

    Bio-IT World | The EMA’s Identification of Medicinal Products (IDMP) standards continues to require significant effort from biopharmas trying to keep up. IDMP was developed to ensure the exchange of reliable medicinal information by providing standard definitions for how companies define and describe products.

    Jul 19, 2024
  • AstraZeneca, Tempus Collaborate on AI Project for Cost Effective Industry R&D

    Bio-IT World | With the rising costs of pharmaceutical industry R&D, achieving breakthroughs in some of the hardest-to-treat diseases, such as cancer, is becoming increasingly expensive. This presents a major challenge to developers in bringing efficient, affordable treatments to patients. AstraZeneca and Tempus teamed up to create a framework that can gather insights, discover novel drug targets, and aim to develop therapeutics for the broader oncology community.

    Jul 17, 2024